We are an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment.

Innovative medical equipment

We enable healthier lives, everywhere, every day

As the leader in women’s health, we deliver life-changing and life-saving diagnostic, detection, and surgical products that are rooted in science, driven by technology, and inspired by our desire to empower women and help healthcare professionals diagnose and treat their patients with growing certainty, precision, and ever-greater peace of mind.

About Us

Featured Products

picture of 3-Dimensions Mammography System

3Dimensions™ Mammography System
picture of Panther Fusion Assays

Panther Fusion® Assays
picture of Brevera Breast Biopsy System

Brevera® Breast Biopsy System
picture of Aptima Herpes Simplex 1&2 assay

Aptima® Herpes Simplex 1&2 assay

Affirm Prone Breast Biopsy System

Affirm® Prone Breast Biopsy System
picture of Horizon DXA System

Horizon® DXA System
picture of ThinPrep Pap test

ThinPrep® Pap test
picture of Fluoroscan InSight Mini C-arm Extremities Imaging System

Fluoroscan® InSight® Mini C-arm Extremities Imaging System
picture of Hologic SARS-CoV-2 Assays

Hologic SARS-CoV-2 Assays
picture of MyoSure Tissue Removal Suite

MyoSure® Tissue Removal Suite
picture of NovaSure Endometrial Ablation

NovaSure® Endometrial Ablation

Financial Fast Facts

Revenue Highlights 1Q23

Non-GAAP
Revenue ($M) 		1Q23 Reported ∆
Vs 1Q22 		CC ∆ Vs 1Q22
Diagnostics1 $559.3 (41.2%) (39.4%)
Breast Health $334.2 (7.0%) (5.2%)
GYN Surgical $154.1 14.7% 17.4%
Skeletal Health $26.6 (1.8%) 0.7%
Total Revenue $1,074.2 (27.0%) (25.1%)
Organic Revenue3 $1,062.5 (27.4%) (25.5%)
Organic ex COVID-194 $898.2 3.8% 6.4%
US Revenue $823.6 (18.6%) -
Intl Revenue $250.6 (45.4%) (39.4%)

Financial Overview 1Q23

Non-GAAP
In Millions ex. EPS 		1Q23 ∆ vs. 1Q22
Revenue ($M) $1,074.2 (27.0%)
Organic Revenue3 $1,062.5 (27.4%)
Organic ex COVID-194 $898.2 (3.8%)
Gross Margin 62.7% (940) bps
Operating Expenses $339.4 1.6%
Operating Margin 31.1% (1,830) bps
Net Margin 24.9% (1,280) bps
Diluted EPS $1.07 (50.7%)
EBITDA $361.0 (52.0%)

Financial Guidance for Second Quarter Fiscal 2023

Non-GAAP 1Q23 Reported vs. 1Q22 CC vs. 1Q22 Organic5 vs. 2Q22
Revenue ($M) $930 - $980 (35.2%) to (31.7%) (34.0%) to (30.5%) (34.0%) to (30.5%)
GAAP EPS $0.60 - $0.70 (66.7%) to (61.1%)
Non-GAAP EPS $0.80 - $0.90 (61.4%) to (56.5%)

Financial Guidance for Full Fiscal 2023

Non-GAAP FY23 Reported vs. FY22 CC vs. FY22 Organic5 vs. FY22
Revenue ($M) $3,850 - $4,000 (20.8%) to (17.7%) (19.8%) to (16.7%) (19.8%) to (16.7%)
GAAP EPS $2.69 - $2.99 (47.6%) to (41.7%)
Non-GAAP EPS $3.55 - $3.85 (41.0%) to (36.0%)

Capital Deployment

Expect strong cash flow in fiscal second quarter and full year 2022

Business development priorities:

  • Tuck-in acquisitions
  • Accretive to revenue, EPS growth rates
  • Attractive ROIC
  • Leverage existing sales channels

Net Debt & Leverage Ratio2

Revenue & CC Growth Rates

2021 Divisional Revenue by Geography

Non-GAAP EPS & Growth Rates

% Net Margin

ROIC

  1. Excluding COVID-19 revenues, global diagnostics revenue increased 15.8% on an organic, constant currency basis.
  2. Net debt is total debt minus cash; leverage ratio is principal debt minus cash to TTM adjusted EBITDA.
  3. Organic revenue excludes divestited Blood business as well as acquired Bolder business.
  4. Total organic revenue excluding COVID-19.
  5. Organic revenue on a constant currency basis. Excludes the divested Blood business and the acquired Bolder business until Q2'23.